Use of NSAIDs via the Rectal Route for the Prevention of Pancreatitis after ERCP in All-Risk Patients: An Updated Meta-Analysis

19Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The aim of this study was to assess the efficacy of the rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing post-ERCP pancreatitis (PEP). We searched database for randomized controlled trials (RCTs) comparing periprocedural rectal administration of NSAIDs with placebo for the prevention of PEP. The rectal administration of NSAIDs significantly decreased the incidence of PEP in the whole patient population (odds ratio (OR): 0.44, 95% confidence interval (CI): 0.30-0.64, P<0.0001), high-risk patients (OR: 0.34, 95% CI: 0.19-0.58, P=0.0001), and all-risk patients (OR: 0.51, 95% CI: 0.31-0.84, P=0.008). The incidence of PEP was reduced by indomethacin (OR: 0.54, 95% CI: 0.36-0.82, P=0.004) and diclofenac (OR: 0.27, 95% CI: 0.15-0.46, P<0.00001). The administration of NSAIDs before (OR: 0.42, 95% CI: 0.25-0.73, P=0.002) or after (OR: 0.39, 95% CI: 0.27-0.56, P<0.00001) ERCP reduced PEP. The NSAIDs were associated with a reduction in mild PEP (OR: 0.55, 95% CI: 0.36-0.83, P=0.004) and moderate-to-severe PEP (OR: 0.47, 95% CI: 0.28-0.79, P=0.004). The rectal administration of NSAIDs reduced the incidence of PEP in high-risk and all-risk patients.

Cite

CITATION STYLE

APA

Yu, L. M., Zhao, K. J., & Lu, B. (2018). Use of NSAIDs via the Rectal Route for the Prevention of Pancreatitis after ERCP in All-Risk Patients: An Updated Meta-Analysis. Gastroenterology Research and Practice. Hindawi Limited. https://doi.org/10.1155/2018/1027530

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free